BioCorRx Inc. (OTC: BICX)

BioCorRx Inc. was incorporated as Cetrone Energy Company on January 28 2008 in the State of Nevada. The company initially pursued development of green renewable fuel sources for agricultural operations specifically biodiesel. After completing a reverse acquisition of Fresh Start Private Inc on October 31 2011 the company ceased its prior operations and became a holding company. Its wholly owned subsidiary now engages in alcoholism and opioid addiction treatment through the BioCorRx Recovery Program and related products. BioCorRx Inc. also controls BioCorRx Pharmaceuticals Inc a clinical stage drug development subsidiary that is seeking U S Food and Drug Administration approval for BICX104 an implantable naltrexone pellet for the treatment of alcohol and opioid use disorders. The company further offers the Beat Addiction Recovery Program which combines proprietary Cognitive Behavioral Therapy modules peer support via a mobile app and medication prescribed by an independent treating physician. Additionally BioCorRx provides the UnCraveRx Weight Loss Management Program a medication assisted weight loss initiative that includes access to concierge on demand wellness specialists such as nutritionists fitness experts and behavioral experts.

BioCorRx Inc. generates revenue from several distinct sources. The company receives licensing fees and royalties from third parties that use its naltrexone implant technology. Under the JPL License Agreement BioCorRx obtained an up front payment of three hundred fifty thousand dollars and is entitled to a monthly fee equal to ten percent of revenue generated by the licensee plus program fees and minimum royalties. The Alpine Creek royalty agreement requires the company to pay fifty percent of gross profit from each Beat Addiction Recovery Treatment sold in the United States until cumulative payments reach one million two hundred fifteen thousand dollars after which a reduced royalty applies. BioCorRx also entered into subscription and royalty agreements with the Lucido and Galligan trusts which provide upfront capital in exchange for a percentage of gross revenue from weight loss treatments. Management services fees are earned from providing administrative and billing support to Joseph DeSanto MD Inc under a contract that pays sixty five percent of the medical corporation’s gross collected monthly revenue. The company supplies the Beat Addiction Recovery Program and the UnCraveRx Weight Loss Program to healthcare providers who pay for access to these therapeutic tools. Supply and distribution sales are generated from the sale of Lucemyra an FDA approved prescription medication for opioid withdrawal that was acquired through an asset purchase agreement with US WorldMeds. Additionally BioCorRx Pharmaceuticals Inc receives grant income from the National Institute on Drug Abuse to support research and development of BICX104 including a recent award of eleven million twenty nine thousand nine hundred seventy seven dollars for methamphetamine use disorder studies.

BioCorRx Inc. operates in the competitive market for addiction treatment therapeutics and related behavioral health programs. The company’s lead product candidate BICX104 is an implantable naltrexone formulation that seeks to improve patient compliance compared to existing oral and injectable options such as Vivitrol. In the broader addiction treatment space BioCorRx faces competition from established pharmaceutical firms that market medications for alcohol and opioid use disorder as well as from providers of counseling and digital health solutions. BioCorRx differentiates itself through its combination of a proprietary long acting implant evidence based cognitive behavioral therapy modules and a mobile app based peer support platform. The company’s ability to integrate medication with behavioral components provides a unique value proposition that may attract providers looking for comprehensive treatment packages. Additionally BioCorRx Pharmaceuticals Inc benefits from government grant support and collaborations with the National Institutes of Health which strengthen its research pipeline and credibility.

BioCorRx Inc. serves a diverse set of customers that include healthcare providers physicians clinics and addiction treatment centers that license its Beat Addiction Recovery Program and UnCraveRx Weight Loss Management Program. The company has entered into specific agreements with entities such as JPL LLC which holds an exclusive license to commercialize the naltrexone implant in Connecticut. Alpine Creek Capital Partners LLC participates in a royalty arrangement tied to Beat Addiction Recovery Treatment sales. The Lucido and Galligan trusts provide upfront funding in exchange for royalties on weight loss treatment revenue. Joseph DeSanto MD Inc receives management services from BioCorRx under a contract that handles billing and administrative functions. US WorldMeds supplies the Lucemyra product through an asset purchase agreement that generates supply and distribution sales for BioCorRx Pharmaceuticals Inc. In addition the company works with various unaffiliated third parties to establish alcoholism and opioid addiction rehabilitation treatment centers and to develop customized addiction rehabilitation programs.